SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
17.25
+0.50 (+2.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.75
Open16.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.75 - 17.30
52 Week Range8.30 - 17.45
Volume34,985
Avg. Volume61,772
Market Cap297.48M
Beta-1.15
PE Ratio (TTM)54.76
EPS (TTM)0.31
Earnings DateJul 14, 2017 - Jul 17, 2017
Forward Dividend & Yield0.20 (1.19%)
Ex-Dividend Date2017-07-26
1y Target Est17.35
Trade prices are not sourced from all markets
  • At $16.7, Is It Time To Buy Simulations Plus Inc (SLP)?
    Simply Wall St.15 days ago

    At $16.7, Is It Time To Buy Simulations Plus Inc (SLP)?

    Simulations Plus Inc (NASDAQ:SLP) trades with a trailing P/E of 52.9x, which is lower than the industry average of 67.3x. While SLP might seem like an attractive stock to buy,Read More...

  • Business Wire18 days ago

    Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2017

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today released preliminary revenues for its fiscal fourth quarter and full fiscal year 2017 ended August 31, 2017.

  • Simulations Plus Sees Composite Rating Move Up To 96
    Investor's Business Daily23 days ago

    Simulations Plus Sees Composite Rating Move Up To 96

    The IBD SmartSelect Composite Rating for Simulations Plus rose from 94 to 96 Thursday.

  • Business Wire2 months ago

    Simulations Plus Announces Senior Management Changes

    Simulations Plus, Inc. , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced changes in its senior management structure.

  • Business Wire2 months ago

    Simulations Plus Releases MembranePlus™ Version 2

    Simulations Plus, Inc. , a leading provider of modeling and simulation solutions for the pharmaceutical, chemicals, and consumer goods industries, today announced that it has released version 2 of its in vitro data analysis program, MembranePlus™.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SLP earnings conference call or presentation 10-Jul-17 8:15pm GMT

    Q3 2017 Simulations Plus Inc Earnings Call

  • Capital Cube2 months ago

    ETFs with exposure to Simulations Plus, Inc. : August 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Simulations Plus, Inc. Here are 5 ETFs with the largest exposure to SLP-US. Comparing the performance and risk of Simulations Plus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire2 months ago

    DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 6A

    DILIsym Services Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released Version 6A of its flagship QSP modeling program, DILIsym.

  • Capital Cube3 months ago

    ETFs with exposure to Simulations Plus, Inc. : July 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Simulations Plus, Inc. Here are 5 ETFs with the largest exposure to SLP-US. Comparing the performance and risk of Simulations Plus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire3 months ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.05 per Share

    Simulations Plus, Inc. , a leading provider of modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and chemicals industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders.

  • Capital Cube3 months ago

    ETFs with exposure to Simulations Plus, Inc. : July 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Simulations Plus, Inc. Here are 5 ETFs with the largest exposure to SLP-US. Comparing the performance and risk of Simulations Plus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Simulations Plus, Inc. :SLP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 12, 2017
    Capital Cube3 months ago

    Simulations Plus, Inc. :SLP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Simulations Plus, Inc. reports financial results for the quarter ended May 31, 2017. We analyze the earnings along side the following peers of Simulations Plus, Inc. – Rennova Health, Inc. (RNVA-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.75 million, Net Earnings of USD 2.08 ... Read more (Read more...)

  • Zacks3 months ago

    Company News for July 12, 2017

    Companies in the News are: FOLD,SLP,ARNA,EVGN,MON

  • Associated Press3 months ago

    Simulations Plus posts 3Q profit

    The Lancaster, California-based company said it had net income of 12 cents per share. Earnings, adjusted for costs related to mergers and acquisitions, came to 13 cents per share. The maker of software ...

  • Business Wire3 months ago

    Simulations Plus Reports Third Quarter FY2017 Financial Results

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its third quarter of fiscal year 2017 and the first nine months of fiscal year 2017 , the period ended May 31, 2017.

  • Accesswire3 months ago

    Investor Network: Simulations Plus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 10, 2017 / Simulations Plus Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q3 Earnings Call to be held July 10, 2017 at 4:15 PM Eastern Time. To ...

  • Business Wire4 months ago

    Simulations Plus Sets Date for 3rd Quarter 2017 Earnings Release and Conference Call

    Simulations Plus, Inc. announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2017 fiscal year, the period ended May 31, 2017, on Monday, July 10, 2017.

  • Business Wire4 months ago

    Simulations Plus Reports Record Preliminary Revenues for Third Quarter FY2017

    Simulations Plus, Inc. , a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the third quarter of its fiscal year 2017, the period ended May 31, 2017 .

  • Business Wire5 months ago

    Simulations Plus Closes Acquisition of DILIsym Services, Inc.

    Simulations Plus, Inc. , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that the Stock Purchase Agreement with DILIsym Services, Inc.

  • Business Wire5 months ago

    Simulations Plus to Present at the 7th Annual LD Micro Invitational

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced that it will be presenting at the 7th Annual LD Micro Invitational on June 6, 2017, at 11 a.m.

  • Business Wire5 months ago

    Simulations Plus to Present at the Needham Emerging Technology Conference

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, announced today that Walt Woltosz, chairman and chief executive officer, will present at the Needham Emerging Technology Conference on Wednesday, May 17, 2017, at 12:50 p.m.

  • Business Wire6 months ago

    Dr. Daniel Weiner Joins Simulations Plus Board of Directors

    Simulations Plus, Inc. , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that Dr. Daniel Weiner, an expert on pharmacokinetic modeling and pharmacodynamics, has become a member of its Board of Directors effective today, filling the vacancy created when Dr.

  • Business Wire6 months ago

    Simulations Plus to Acquire DILIsym Services, Inc.

    Simulations Plus, Inc. , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has entered into a Stock Purchase Agreement with DILIsym Services, Inc.

  • Capital Cube6 months ago

    ETFs with exposure to Simulations Plus, Inc. : April 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Simulations Plus, Inc. Here are 5 ETFs with the largest exposure to SLP-US. Comparing the performance and risk of Simulations Plus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire6 months ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.05 per Share

    Simulations Plus, Inc. , a leading provider of modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and chemicals industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders.